Stephens Consulting, LLC Aldeyra Therapeutics, Inc. Transaction History
Stephens Consulting, LLC
- $392 Billion
- Q3 2024
A detailed history of Stephens Consulting, LLC transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Stephens Consulting, LLC holds 1,000 shares of ALDX stock, worth $4,800. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,000
Previous 1,000
-0.0%
Holding current value
$4,800
Previous $3.31 Million
62.84%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ALDX
# of Institutions
117Shares Held
36.4MCall Options Held
196KPut Options Held
142K-
Perceptive Advisors LLC New York, NY9.28MShares$44.5 Million1.31% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$26.3 Million14.56% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.76MShares$18.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$17.4 Million0.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO1.88MShares$9.03 Million0.24% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $280M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...